Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
As growing evidence shows that engagement with politics is associated with worsening mental and physical health, a bumper election year and increasing polarization could affect millions.
A translational study and phase 1 trial show that the JAK inhibitor ruxolitinib stimulates responses to nivolumab in patients with refractory Hodgkin lymphoma.
As healthcare becomes more data-driven and precise, promising greater accuracy, targeted use of resources and healthier populations, we ask what it will take to realize these benefits in local and global contexts.
Precision health in low- and middle-income countries should focus on disease prevention and implementation in order to be cost-effective and impactful.
Dozens of clinical trials are testing new mRNA vaccines, using machine learning to identify antigens, and embracing new technologies such as self-amplifying RNA.
In adults with moderate to severe obstructive sleep apnea and obesity, tirzepatide showed several improvements in sleep characteristics with an acceptable safety profile, relative to control.
A recent workshop brought together global leaders in diabetes to assess existing approaches to disease heterogeneity and to identify research gaps, with a goal of achieving precision diabetology for all patients globally.
The European Association for the Study of Obesity presents a new framework for the diagnosis, staging and management of obesity in adults to better align with the concept of obesity as an adiposity-based chronic disease.
A randomized trial shows that a low-cost, accessible, walking-based intervention reduced low-back-pain recurrence, and could offer a scalable approach to tackling this common condition.
Alzheimer’s disease can be treated by targeting amyloid-β plaques and diagnosed in vivo by biomarkers, prompting the revision of criteria for the diagnosis and staging of this disease.
A phase 3 trial establishes 177Lu-dotatate plus long-acting octreotide as a new first-line treatment for patients with high-grade gastroenteropancreatic neuroendocrine tumors.
Fortunate Machingura heads CeSHHAR Zimbabwe’s Climate, Environment, and Health Department and is also a lecturer at the Liverpool School of Tropical Medicine. She describes her pivot from HIV research to another crucial challenge facing Africa: climate change.
For precision genetic medicines to fulfill their potential as treatments for ultra-rare diseases, fresh approaches to academic–industry partnerships and data sharing are needed, together with regulatory change and adaptation of reimbursement models.